Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vuk Zdinjak

Zelira's Zenivol, Clinically Validated Cannabinoid Medication For Insomnia, Gets Regulatory Approval In Germany

Zelira Therapeutics Ltd’s (OTCQB:ZLDAF) (ASX:ZLD) insomnia medication Zenivol has achieved formal approval from German regulatory authority BfArM to launch in the German medical cannabis market.

According to the company, Zenivol is the world's first and only clinically validated, pharmaceutical-grade, cannabis-based sleep medication. Zenivol's clinical research was peer reviewed in the Journal of Sleep. It is currently available by prescription in Australia under the country's legal cannabis regulations.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.